EP 4146260 A2 20230315 - MODIFIED MRNA FOR MULTICELL TRANSFORMATION
Title (en)
MODIFIED MRNA FOR MULTICELL TRANSFORMATION
Title (de)
MODIFIZIERTE MRNA ZUR MEHRZELLENTRANSFORMATION
Title (fr)
ARNM MODIFIÉ POUR TRANSFORMATION MULTICELLULAIRE
Publication
Application
Priority
- US 202016869642 A 20200508
- US 2021031204 W 20210507
Abstract (en)
[origin: WO2021226413A2] Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro. Codon modification of the mRNA can optimize expression of an immunogenic polypeptide in cancer cells.
IPC 8 full level
A61K 39/00 (2006.01); A61K 45/06 (2006.01)
CPC (source: EP KR)
A61K 39/0011 (2013.01 - EP KR); A61K 39/092 (2013.01 - EP KR); A61P 31/04 (2018.01 - EP); A61P 35/00 (2018.01 - EP KR); C07K 14/315 (2013.01 - KR); A61K 2039/53 (2013.01 - EP KR); A61K 2039/552 (2013.01 - EP KR); A61K 2039/804 (2018.08 - EP KR); A61K 2039/876 (2018.08 - EP KR); C12N 2800/22 (2013.01 - KR); C12N 2830/50 (2013.01 - KR)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2021226413 A2 20211111; WO 2021226413 A3 20211230; AU 2021269036 A1 20221215; CA 3178223 A1 20211111; CN 115052621 A 20220913; EP 4146260 A2 20230315; EP 4146260 A4 20240626; JP 2023524818 A 20230613; KR 20230009462 A 20230117
DOCDB simple family (application)
US 2021031204 W 20210507; AU 2021269036 A 20210507; CA 3178223 A 20210507; CN 202180007853 A 20210507; EP 21800236 A 20210507; JP 2022567590 A 20210507; KR 20227043200 A 20210507